Drug Trial Radar · NCT02924688
A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma
Last checked: Nov 19, 2026Latest source record: Mar 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,436
Actual
Start
Oct 13, 2016
Primary completion
Feb 22, 2019
Study completion Feb 22, 2019
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Oct 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A once-daily 'closed' triple FDC therapy of FF/UMEC/VI via a single ELLIPTA® dry powder inhaler (DPI) is being developed by GlaxoSmithKline (GSK) with the aim of providing a new treatment option for the management of asthma by improving lung function, health-related quality of life (HRQoL) and symptom control over established combination therapies. This is a phase III, multi-center, active-controlled, double-blind, parallel-group study to compare the efficacy, safety and tolerability of the FDC of FF/UMEC/VI with the FDC of FF/VI. This study has 5 phases: Pre-Screening (Visit 0), Screening/Run-in, Enrolment/Stabilization, Randomization/Treatment, and Follow up. At Visit 1 (Screening), subjects meeting all protocol defined inclusion/exclusion criteria will enter a 3-week run-in period and will receive fixed dose inhaled corticosteroid/long-acting beta agonist (ICS/LABA) (fluticasone/salmeterol, 250/50 micrograms (mcg), via the DISKUS® DPI) one inhalation twice a day. At Visit 2 (Enrolment), eligible subjects will be enrolled into the 2-week stabilization period to receive FF/VI (100/25 mcg via the ELLIPTA DPI once a day, in the morning). At the conclusion of the stabilization period (Visit 3), all subjects who meet the pre-defined randomization criteria will be randomized 1:1:1:1:1:1 during the treatment period to receive either FF/UMEC/VI (100/62.5/25 mcg; 200/62.5/25 mcg; 100/31.25/25 mcg; 200/31.25/25 mcg) or FF/VI (100/25 mcg; 200/25 mcg) via the ELLIPTA DPI once daily in the morning. The duration of the treatment period is variable but will be a minimum of 24 weeks and a maximum of 52 weeks. Subjects will have up to 6 on-treatment clinic visits scheduled at Visits 3, 4, 5, 6, 7 and 8/End of Study (EOS) (Weeks 0, 4, 12, 24, 36 and 52, respectively). A follow-up visit will be conducted approximately 7 days after the end of treatment period or, if applicable, after the early withdrawal visit. Subjects will be provided with short acting albuterol/salbutamol to be used on an as-needed basis (rescue medication) throughout the study. Approximately 2250 subjects will be randomized, with approximately 375 subjects randomized to each of the 6 double-blind treatment arms to ensure approximately 337 evaluable subjects per treatment arm. DISKUS and ELLIPTA are registered trademarks of GSK groups of companies.
Conditions
- Asthma
Interventions
FF/UMEC/VI (100/31.25/25) mcgDrug
Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
FF/UMEC/VI (100/62.5/25) mcgDrug
Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
FF/UMEC/VI (200/31.25/25) mcgDrug
Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
FF/UMEC/VI (200/62.5/25) mcgDrug
Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
FF/VI (100/25) mcgDrug
Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
FF/VI (200/25) mcgDrug
Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
Fluticasone/salmeterol (FSC)Drug
Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
Albuterol/salbutamolDrug
This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
ELLIPTA DPIDevice
The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
DISKUS DPIDevice
The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
METERED-DOSE INHALER (MDI)Device
Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24Time frame: Baseline (pre-dose at Day 1) and Week 24
Locations
409 sites in 15 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Mobile, Alabama
GSK Investigational Site
Montgomery, Alabama
GSK Investigational Site
Gilbert, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Canton, California
GSK Investigational Site
Encinitas, California
GSK Investigational Site
Escondico, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
Huntington Beach, California
GSK Investigational Site
La Jolla, California
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Oxnard, California
GSK Investigational Site
Rolling Hills Estates, California
GSK Investigational Site
Roseville, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Diego, California
GSK Investigational Site
San Jose, California
GSK Investigational Site
Aurora, Colorado
GSK Investigational Site
Colorado Springs, Colorado
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Lafayette, Colorado
GSK Investigational Site
Aventura, Florida
GSK Investigational Site
Brandon, Florida
GSK Investigational Site
Hollywood, Florida
GSK Investigational Site
Jupiter, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Ocoee, Florida
GSK Investigational Site
St. Petersburg, Florida
GSK Investigational Site
Tallahassee, Florida
GSK Investigational Site
Adairsville, Georgia
GSK Investigational Site
Columbus, Georgia
GSK Investigational Site
Normal, Illinois
GSK Investigational Site
River Forest, Illinois
GSK Investigational Site
Michigan City, Indiana
GSK Investigational Site
South Bend, Indiana
GSK Investigational Site
Topeka, Kansas
Showing 40 of 409 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.